Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM). However, many patients have disease that does not respond to bortezomib, whereas others develop resi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kuhn, Deborah J., Chen, Qing, Voorhees, Peter M., Strader, John S., Shenk, Kevin D., Sun, Congcong M., Demo, Susan D., Bennett, Mark K., van Leeuwen, Fijs W. B., Chanan-Khan, Asher A., Orlowski, Robert Z.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2007
Matèries:
Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2200918/
https://ncbi.nlm.nih.gov/pubmed/17591945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-01-065888
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars